[{"id":"b17610a4-7f1e-4ca3-bde1-2677610463ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05932264","created_at":"2023-07-06T16:10:07.113Z","updated_at":"2024-07-02T16:35:43.864Z","phase":"Phase 2","brief_title":"Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05932264","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • BRAF • ALK • TP53 • ROS1","pipe":" | ","alterations":" TP53 mutation • ALK positive • TP53 R175H • TP53 R248Q • TP53 Y220C • TP53 R273H • TP53 R273C","tags":["EGFR • BRAF • ALK • TP53 • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • TP53 R175H • TP53 R248Q • TP53 Y220C • TP53 R273H • TP53 R273C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-06"}]